Skip to main content
PG logo

PG — Investor Relations & Filings

Ticker · 6550 ISIN · KYG7171A1085 TW Manufacturing
Open in API
Filings indexed 59 across all filing types
Latest filing 2026-05-25 Regulatory Filings
Country TW Taiwan
Listing TW 6550

About PG

www.polarispharma.com

Polaris Group is a biotechnology company dedicated to the development of novel anti-cancer therapies and the provision of Contract Development and Manufacturing Organization (CDMO) services. The company’s core research focuses on ADI-PEG 20 (pegargiminase), a biological agent that utilizes metabolic therapy to target arginine-dependent cancers. This candidate is currently in late-stage clinical development for multiple indications, including mesothelioma, soft tissue sarcoma, and hepatocellular carcinoma. Polaris Group maintains a vertically integrated business model, encompassing drug design, clinical trial management, and internal manufacturing capabilities. It operates cGMP-compliant facilities and has expanded its CDMO portfolio to include complex injectables and synthetic peptides. The company aims to deliver innovative treatment options by leveraging its proprietary technology and global clinical partnerships.

Recent filings

Filing Released Lang Actions
115年05月僑外投資持股
Regulatory Filings Classification · 88% confidence The document is a standardized regulatory disclosure from the Taiwan Market Observation Post System detailing foreign and Mainland China investor shareholdings by category before and after a recent change (cash capital increase + shareholder meeting). It is not an earnings release, financial report, AGM material, or any of the other specialized categories. It fits the general regulatory announcement category (RNS).
2026-05-25 Chinese
公告本公司114年第二次私募普通股收足股款暨增資基準日
Share Issue/Capital Change Classification · 91% confidence The document is a regulatory announcement from a listed company disclosing completion of a private placement of 34.9 million new common shares, the full subscription payment received, and setting the capital increase record date. This is clearly an announcement of a new share issue and related capital change. Therefore it matches Share Issue/Capital Change.
2026-05-22 Chinese
公告更正本公司115年董事選任時持股股數
Regulatory Filings Classification · 83% confidence The document is a brief correction notice filed via the public disclosure system (公開資訊觀測站) to amend a previously reported board‐member shareholding figure. It contains no financial statements, no dividend or transaction details, no substantive report content—just a misc. regulatory correction. This clearly falls into the catch‐all “Regulatory Filings” category (RNS).
2026-05-21 Chinese
115年第1季財務報告書 — 202601_6550_AI1.pdf
Interim / Quarterly Report Classification · 95% confidence The document is a consolidated financial report and auditor review for the first quarter of 2026 and 2025, including full interim financial statements (balance sheet, income statement, cash flows, equity changes) and detailed notes prepared under IFRS 34. This is a comprehensive, period-specific financial report for a quarter, matching the definition of an Interim/Quarterly Report. Q1 2026
2026-05-14 Chinese
115年第1季大陸投資
Regulatory Filings Classification · 45% confidence The document is a Mainland China investment disclosure table required by the Taiwan public information observatory (“公開資訊觀測站”) showing cross-border investment details for Q1 (年度115 季別01) of 北極星藥業-KY. It is not a full interim report, earnings release, or management presentation, nor does it announce publication of another report. It is a standalone regulatory disclosure with specific investment data, so it falls into the general Regulatory Filings category (RNS).
2026-05-14 Chinese
115年第1季海外子公司投資
Interim / Quarterly Report Classification · 85% confidence The document is a detailed schedule of equity-method investments for the company’s first quarter (‘115年1季申報作業’) showing actual financial balances at period-end and recognized profit/loss. It is substantive financial data for an interim period (first quarter) rather than a mere announcement or summary. This aligns with an Interim/Quarterly Report. Q1 2026
2026-05-14 Chinese

Browse filings by year

1 year

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.